Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alphamab OncologyALMOF 12 EV-to-OCF is -49.84 as of Aug. 28, 2026. GuruFocus rates ALMOF with a GF Score™ of 12/100 and a GF Value™ of $0.87 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,409 Biotechnology companies, Alphamab Oncology ranks better than 92.48% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Alphamab Oncology's Enterprise Value is $862.21 Mil.
Alphamab Oncology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-17.30 Mil. Therefore, Alphamab Oncology's EV-to-OCF for today is -49.84.
The historical rank and industry rank for Alphamab Oncology's EV-to-OCF or its related term are showing as below:
ALMOF'
s EV-to-OCF Range Over the Past 10 Years
Min: -74.89 Med: -14.57 Max: 59.9
Current: -50.21
During the past 9 years, the highest EV-to-OCF of Alphamab Oncology was 59.90. The lowest was -74.89. And the median was -14.57.
ALMOF's EV-to-OCF is ranked better than 92.48% of 1409
companies
in the Biotechnology industry
Industry Median: -3.71
vs ALMOF: -50.21
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alphamab Oncology's PE Ratio (TTM) for today is calculated as:
Alphamab Oncology's share price for today is $1.02155.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Alphamab Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.017.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Alphamab Oncology EV-to-OCF Related Terms
Alphamab Oncology EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Alphamab Oncology's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alphamab Oncology's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alphamab Oncology EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alphamab Oncology's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Alphamab Oncology's EV-to-OCF falls into.
Alphamab Oncology's current Enterprise Value is $862.21 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Alphamab Oncology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-17.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alphamab Oncology (ALMOF) has a EV-to-OCF of -49.84 as of Aug. 28, 2026. According to the industry distribution chart, Alphamab Oncology ranks #106 out of 1409 companies in the Biotechnology industry, placing it in the top 7.5%.
Is Alphamab Oncology's EV-to-OCF too high?
Alphamab Oncology's current EV-to-OCF is -49.84. Based on the distribution chart, Alphamab Oncology ranks #106 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alphamab Oncology has a GF Score™ of 12/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alphamab Oncology ranks #106 out of 1409 companies for EV-to-OCF. This places Alphamab Oncology in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Alphamab Oncology's current EV-to-OCF is -49.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Based on GuruFocus' analysis, Alphamab Oncology (ALMOF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $1.02 — trading 17.4% above its estimated fair value. The current EV-to-OCF is -49.84. Alphamab Oncology's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Alphamab Oncology (ALMOF), the current EV-to-OCF is -49.84 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alphamab Oncology (ALMOF) Overvalued in 2026?
Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued.
The current stock price of $1.02 is trading 17.4% above its estimated GF Value™ of $0.87.
GuruFocus considers Alphamab Oncology to be Modestly Overvalued.
Key valuation signals for ALMOF:
EV-to-OCF: -49.84
GF Value™: $0.87 vs. price of $1.02 (17.4% above fair value)
No single metric tells the full story. See the ALMOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
12GF Score
Get the complete analysis for ALMOF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMOF has been successfully added to your 
